IDEAS home Printed from
   My bibliography  Save this article

Present at the biotechnological revolution: transformation of technological identity for a large incumbent pharmaceutical firm


  • Zucker, Lynne G.
  • Darby, Michael R.


No abstract is available for this item.

Suggested Citation

  • Zucker, Lynne G. & Darby, Michael R., 1997. "Present at the biotechnological revolution: transformation of technological identity for a large incumbent pharmaceutical firm," Research Policy, Elsevier, vol. 26(4-5), pages 429-446, December.
  • Handle: RePEc:eee:respol:v:26:y:1997:i:4-5:p:429-446

    Download full text from publisher

    File URL:
    Download Restriction: Full text for ScienceDirect subscribers only

    As the access to this document is restricted, you may want to search for a different version of it.

    References listed on IDEAS

    1. Aghion, P. & Tirole, J., 1993. "On the Management of Innovation," Working papers 93-12, Massachusetts Institute of Technology (MIT), Department of Economics.
    2. Klevorick, Alvin K. & Levin, Richard C. & Nelson, Richard R. & Winter, Sidney G., 1995. "On the sources and significance of interindustry differences in technological opportunities," Research Policy, Elsevier, vol. 24(2), pages 185-205, March.
    3. Comanor, William S, 1986. "The Political Economy of the Pharmaceutical Industry," Journal of Economic Literature, American Economic Association, vol. 24(3), pages 1178-1217, September.
    4. Lynne G. Zucker & Michael R. Darby, 1996. "Costly Information in Firm Transformation, Exit, or Persistent Failure," NBER Working Papers 5577, National Bureau of Economic Research, Inc.
    5. Demsetz, Harold, 1988. "The Theory of the Firm Revisited," Journal of Law, Economics, and Organization, Oxford University Press, vol. 4(1), pages 141-161, Spring.
    6. Reinganum, Jennifer F, 1983. "Uncertain Innovation and the Persistence of Monopoly," American Economic Review, American Economic Association, vol. 73(4), pages 741-748, September.
    7. Dosi, Giovanni, 1993. "Technological paradigms and technological trajectories : A suggested interpretation of the determinants and directions of technical change," Research Policy, Elsevier, vol. 22(2), pages 102-103, April.
    8. Arora, Ashish & Gambardella, Alfonso, 1994. "Evaluating technological information and utilizing it : Scientific knowledge, technological capability, and external linkages in biotechnology," Journal of Economic Behavior & Organization, Elsevier, vol. 24(1), pages 91-114, June.
    9. Philippe Aghion & Jean Tirole, 1994. "The Management of Innovation," The Quarterly Journal of Economics, Oxford University Press, vol. 109(4), pages 1185-1209.
    10. Pertti H. Lounamaa & James G. March, 1987. "Adaptive Coordination of a Learning Team," Management Science, INFORMS, vol. 33(1), pages 107-123, January.
    11. Reinganum, Jennifer F., 1989. "The timing of innovation: Research, development, and diffusion," Handbook of Industrial Organization,in: R. Schmalensee & R. Willig (ed.), Handbook of Industrial Organization, edition 1, volume 1, chapter 14, pages 849-908 Elsevier.
    Full references (including those not matched with items on IDEAS)


    Citations are extracted by the CitEc Project, subscribe to its RSS feed for this item.

    Cited by:

    1. Marc-Hubert Depret & Abdelillah Hamdouch, 2004. "La gouvernance des jeunes entreprises innovantes:un éclairage analytique à partir du cas des sociétés de biotechnologies," Revue Finance Contrôle Stratégie,, vol. 7(2), pages 67-94, June.
    2. Huffman, Wallace E. & Just, Richard E., 1999. "The organization of agricultural research in western developed countries," Agricultural Economics, Blackwell, vol. 21(1), pages 1-18, August.
    3. Gilsing, Victor & Nooteboom, Bart, 2006. "Exploration and exploitation in innovation systems: The case of pharmaceutical biotechnology," Research Policy, Elsevier, vol. 35(1), pages 1-23, February.
    4. Sternitzke, Christian, 2010. "Knowledge sources, patent protection, and commercialization of pharmaceutical innovations," Research Policy, Elsevier, vol. 39(6), pages 810-821, July.
    5. Lynne G. Zucker & Michael R. Darby, 2014. "Defacto and Deeded Intellectual Property: Knowledge-Driven Co-Evolution of Firm Collaboration Boundaries and IPR Stragtegy," Annals of Economics and Statistics, GENES, issue 115-116, pages 221-251.
    6. Kafouros, Mario & Wang, Chengqi & Piperopoulos, Panagiotis & Zhang, Mingshen, 2015. "Academic collaborations and firm innovation performance in China: The role of region-specific institutions," Research Policy, Elsevier, vol. 44(3), pages 803-817.
    7. Fabienne Orsi & Jean-Paul Moatti, 2001. "D'un droit de propriété intellectuelle sur le vivant aux firmes de génomique : vers une marchandisation de la connaissance scientifique sur le génome humain," Économie et Prévision, Programme National Persée, vol. 150(4), pages 123-138.
    8. Zhifeng Yin & Qiang Zhi, 2017. "Dancing with the academic elite: a promotion or hindrance of research production?," Scientometrics, Springer;Akadémiai Kiadó, vol. 110(1), pages 17-41, January.
    9. McMillan, G. Steven & Narin, Francis & Deeds, David L., 2000. "An analysis of the critical role of public science in innovation: the case of biotechnology," Research Policy, Elsevier, vol. 29(1), pages 1-8, January.
    10. Lynne G. Zucker & Michael R. Darby & Yusheng Peng, 1998. "Fundamentals or Population Dynamics and the Geographic Distribution of U.S. Biotechnology Enterprises, 1976-1989," NBER Working Papers 6414, National Bureau of Economic Research, Inc.
    11. Anna Giunta & Filippo M. Pericoli & Eleonora Pierucci, 2016. "University–Industry collaboration in the biopharmaceuticals: the Italian case," The Journal of Technology Transfer, Springer, vol. 41(4), pages 818-840, August.
    12. Lynne G. Zucker & Michael R. Darby, 2009. "Star Scientists, Innovation and Regional and National Immigration," Chapters,in: Entrepreneurship and Openness, chapter 6 Edward Elgar Publishing.
    13. repec:bla:stratm:v:38:y:2017:i:2:p:395-414 is not listed on IDEAS
    14. Wry, Tyler & Lounsbury, Michael, 2013. "Contextualizing the categorical imperative: Category linkages, technology focus, and resource acquisition in nanotechnology entrepreneurship," Journal of Business Venturing, Elsevier, vol. 28(1), pages 117-133.
    15. repec:hal:journl:hal-00424183 is not listed on IDEAS
    16. Giovanni Abramo & Ciriaco Andrea D’Angelo & Anastasiia Soldatenkova, 2017. "How long do top scientists maintain their stardom? An analysis by region, gender and discipline: evidence from Italy," Scientometrics, Springer;Akadémiai Kiadó, vol. 110(2), pages 867-877, February.
    17. Michael R. Darby & Lynne G. Zucker, 1999. "Local Academic Science Driving Organizational Change: The Adoption of Biotechnology by Japanese Firms," NBER Working Papers 7248, National Bureau of Economic Research, Inc.
    18. Kneller, Robert, 2003. "Autarkic drug discovery in Japanese pharmaceutical companies: insights into national differences in industrial innovation," Research Policy, Elsevier, vol. 32(10), pages 1805-1827, December.
    19. Hopkins, Michael M. & Nightingale, Paul, 2006. "Strategic risk management using complementary assets: Organizational capabilities and the commercialization of human genetic testing in the UK," Research Policy, Elsevier, vol. 35(3), pages 355-374, April.
    20. Kwangsoo Shin & Sang Ji Kim & Gunno Park, 2016. "How does the partner type in R&D alliances impact technological innovation performance? A study on the Korean biotechnology industry," Asia Pacific Journal of Management, Springer, vol. 33(1), pages 141-164, March.
    21. Masao Nakamura & Robert Dalpé, 2003. "Interaction between public research organizations and industry in biotechnology," Managerial and Decision Economics, John Wiley & Sons, Ltd., vol. 24(2-3), pages 171-185.
    22. Amit Jain, 2016. "Learning by hiring and change to organizational knowledge: Countering obsolescence as organizations age," Strategic Management Journal, Wiley Blackwell, vol. 37(8), pages 1667-1687, August.
    23. Rebecca R. Kehoe & Daniel Tzabbar, 2015. "Lighting the way or stealing the shine? An examination of the duality in star scientists' effects on firm innovative performance," Strategic Management Journal, Wiley Blackwell, vol. 36(5), pages 709-727, May.
    24. Williams, David R., 2013. "Human and financial capital as determinants of biopharmaceutical IPO de-listings," Journal of Business Research, Elsevier, vol. 66(12), pages 2612-2618.

    More about this item


    Access and download statistics


    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:eee:respol:v:26:y:1997:i:4-5:p:429-446. See general information about how to correct material in RePEc.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: (Dana Niculescu). General contact details of provider: .

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service hosted by the Research Division of the Federal Reserve Bank of St. Louis . RePEc uses bibliographic data supplied by the respective publishers.